Scientists test Triple-Threat drug cocktail against spreading prostate cancer
NCT ID NCT04477512
Summary
This early-stage trial tested the safety of combining three different cancer drugs—cabozantinib, abiraterone, and nivolumab—along with standard hormone therapy for men with newly diagnosed advanced prostate cancer that has spread. The main goal was to find a safe dose for future studies by monitoring side effects in 18 participants. Researchers hoped this combination would be tolerable and help control the cancer longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE REFRACTORY PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.